conatumumab
A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.
| Synonym: | anti-TRAIL receptor 2 monoclonal antibody AMG 655 immunoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member 10b (death receptor 5, trail-R2, CD262 antigen)) monoclonal XG1-048 (Arg(Sup 219),Glu(Sup 361),Met(Sup 363))gamma-1 heavy chain (225-215')-disulphide with kappa light chain (231-231'':234-234'')-bisdisulphide dimer |
|---|---|
| Code name: | AMG 655 |
| Chemical structure: | immunoglobulin G1, anti-(human cytokine receptor DR5 (death receptor 5)) (human monoclonal XG1-048 v w heavy chain), disulfide with human monoclonal XG1-048 v w light chain, dimer immunoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member 10B (death receptor 5, TRAIL-R2, CD262 antigen)); human monoclonal XG1-048 [Arg219,Glu361,Met363]γ1 heavy chain (225-215')-disulfide with κ light chain (231- 231'':234-234'')-bisdisulfide dimer |